Splash Beverage Group, INC 8-K filings

Splash Beverage Group, Inc. announced its intention to change its corporate name to Endovia Health Sciences, Inc., effective August 24, 2026, signaling a strategic shift into the cannabinoid health sciences sector.

Splash Beverage Group, Inc. has filed amendments to its Articles of Incorporation to change its corporate name to Endovia Health Sciences, Inc., effective upon filing with the Nevada Secretary of State.

Splash Beverage Group announces a collaboration with Lupvindol Biosciences to advance CannEpil for veterinary use in companion-animal oncology and chronic pain management.

Splash Beverage Group enters a material definitive agreement with Lupvindol Biosciences Ltd. to develop a cannabinoid-based animal drug.

Splash Beverage Group announces an amendment to its exclusive global license for CannEpil, expanding its use to veterinary applications and adjusting royalty rates.

Splash Beverage Group has amended its exclusive global license for CannEpil to include veterinary applications, establishing a second regulated pharmaceutical development program.

Splash Beverage Group has amended settlement agreements with prior investors, extending payment deadlines and adjusting settlement amounts.

Splash Beverage Group, Inc. is implementing a one-for-four reverse stock split and has had its common stock trading halted by NYSE American due to trading below $0.10 per share.

Splash Beverage Group announced settlements with creditors reducing $3.3 million in liabilities to $550,000 and approved a 1-for-4 reverse stock split to aid NYSE American compliance.

Splash Beverage Group has entered into a letter agreement to settle its outstanding loan obligations totaling $2,834,689 for a reduced payment of $301,800.55.

Splash Beverage Group announced the sale of over 9.2 million shares of common stock, raising approximately $1.26 million in gross proceeds.

Splash Beverage Group announced NYSE American has accepted its plan to regain compliance with listing standards, granting a compliance period through January 29, 2027.

Splash Beverage Group secures exclusive worldwide rights to CannEpil, a cannabinoid formulation for drug-resistant epilepsy, through a new license agreement with Argent Biopharma.

Splash Beverage Group has acquired exclusive global licensing rights for CannEpil, a cannabinoid-based epilepsy therapy, from Argent BioPharma Limited, aiming to leverage existing European access and pursue U.S. regulatory advancement.

Splash Beverage Group issued 767,953 shares of common stock to C/M Capital Master Fund, LP for $117,036 in gross proceeds.

Splash Beverage Group announced a strategic CDN$300,000 investment in Avicanna Inc., a cannabinoid biopharmaceutical company, as part of its transformation into a health and wellness platform.

Splash Beverage Group appoints new COO, invests in Avicanna, and proposes a strategic RSU plan to drive transformation.

Splash Beverage Group provides an update on its NYSE American compliance plan and ongoing strategic transaction initiatives, aiming to strengthen its financial position and explore opportunities in the cannabinoid wellness sector.

Splash Beverage Group announces Brady Cobb as Interim CEO, signaling a strategic pivot towards wellness and cannabinoid markets while William Meissner resigns as President.

Splash Beverage Group received a notice from the NYSE for non-compliance with shareholder equity requirements, with a plan to regain compliance due by May 29, 2026.

Splash Beverage Group, Inc. has appointed Francis Knuettel II as a new member of its Board of Directors, effective April 27, 2026.

Splash Beverage Group faces board departures, debt settlement extensions, and a $2.8 million loan default demand.

Splash Beverage Group, Inc. has officially withdrawn the designation of its Series A Preferred Stock, effective April 17, 2026, with no shares currently issued or outstanding.

Splash Beverage Group, Inc. has entered a letter of intent for a potential business combination with Medterra CBD, LLC, valuing Medterra at $37.6 million.

Splash Beverage Group announced a non-binding letter of intent to merge with Medterra CBD, aiming to transform into a cannabinoid wellness platform.

Splash Beverage Group appointed Brady Cobb to its Board of Directors, signaling a strategic pivot towards high-growth consumer categories including federally compliant CBD and hemp.

Splash Beverage Group, Inc. disclosed recent unregistered sales of common stock and conversions of convertible promissory notes, resulting in share dilution.

Splash Beverage Group announced that its Chispo Tequila has been selected as the house tequila for Senor Frogs across initial locations in Florida, the Bahamas, and Mexico.

Splash Beverage Group issued a promissory note up to $700,000 to an investor, replacing commitment shares under a prior equity line of credit agreement.

Splash Beverage Group, Inc. announced the immediate appointment of Martin Scott as its interim Chief Financial Officer, bringing extensive financial and consulting experience to the role.